Acquired Company

Leisure Acquisition Corp. completed its merger with Ensysce Biosciences, Inc. on June 30, 2021, with the combined company commencing trading under ENSC on Nasdaq on July 1, 2021.

Ensysce Biosciences Inc. is a clinical-stage biotechnology firm based in La Jolla, California, specializing in the development of pioneering prescription drug solutions aimed at revolutionizing pain management. The company is particularly focused on creating advanced drug delivery systems that aim to reduce the risks of opioid dependence, addressing a critical challenge in modern healthcare. With its robust commitment to pharmaceutical research and development, Ensysce is poised to make significant contributions to the biopharmaceutical landscape, offering a compelling investment opportunity for institutional investors seeking innovation in pain management therapies. Show more

Location: 7946 IVANHOE AVENUE, LA JOLLA, CA, UNITED STATES, 92037, La Jolla, CA, 92037, USA | Website: https://www.ensysce.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.638M

52 Wk Range

$0.69 - $6.83

Previous Close

$0.72

Open

$0.73

Volume

106,197

Day Range

$0.69 - $0.73

Enterprise Value

1.33M

Cash

1.673M

Avg Qtr Burn

-1.866M

Insider Ownership

0.29%

Institutional Own.

10.59%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PF614 Details Severe Pain	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PF614-MPAR Details Severe Pain	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.